Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2097 • ACR Convergence 2023
Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque
Natalia Guajardo-Jauregui¹, Iris Colunga², José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Rosa Arvizu-Rivera³ and Jesus Alberto Cardenas-De la Garza⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Cardiovascular disease is the major cause of death in rheumatoid arthritis (RA) patients. Cardiovascular risk algorithms are employed to assess the likelihood of experiencing…
Abstract Number: 2114 • ACR Convergence 2023
The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function
Sho Fukui¹, Wolfgang Winkelmayer², Sara Tedeschi¹, Javier Marrugo¹, Hongshu Guan¹, Leslie Harrold³, Heather Litman³, Tomohiro Shinozaki⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Baylor College of Medicine, Houston, TX, ³CorEvitas, LLC, Waltham, MA, ⁴Tokyo University of Science, Tokyo, Japan, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
Abstract Number: 2130 • ACR Convergence 2023
Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab
Yi-Min Huang¹, Chieh-An Chuang², Jui-Hung Kao², Yen-Chun Lin², Jen-Hao Chen³, Chiao-Feng Cheng⁴, Cheng-Hsun Lu⁴, Yu-Min Kuo⁴, Chieh-Yu Shen⁴, Chin-Hsiu Liu⁵, Ko-Jen Li⁴, Song-Chou Hsieh⁴, Jung-Yien Chien⁴ and Po-Ren Hsueh⁴, ¹National Taiwan University Cancer Center, Taipei City, Taiwan, ²National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan, ³National Taiwan University Cancer Center, Taipei, Taiwan, ⁴National Taiwan University Hospital, Taipei, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Patients with rheumatoid arthritis (RA) are susceptible toPneumocystis jiroveciicolonization and prone to develop life-threateningPneumocystispneumonia (PCP). An increased risk ofP. jiroveciicolonization and PCP was found…
Abstract Number: 2146 • ACR Convergence 2023
After JAK Inhibitor Failure, “Switching” or “Cycling”?
Pablo Francisco Muñoz Martínez¹, Laura Mas Sanchez², Elena Grau Garcia³, Carmen Riesco Barcena³, Anderson Victor Huaylla Quispe³, Alba Maria Torrat Noves³, Daniel Ramos Castro³, Belen Villanueva Mañez³, Iago Alcantara Alvarez³, Samuel Leal Rodriguez³, Elvira Vicens Bernabeu³, Jose Eloy Oller Rodriguez³, Ines Canovas Olmos³, Ernesto Tovar Sugrañes³, Carmen Najera Herranz³, Isabel Martinez Cordellat³, Hikmat Charia³, Rosa Negueroles Albuixech³, Marta De la Rubia Navarro², Luis Gonzalez Puig³, Jose Ivorra Cortes³ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Sagunto, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: The appearance of JAK inhibitors (JAKi) in the last few years has proved a great clinical application in rheumatic pathology and it has become…
Abstract Number: 2163 • ACR Convergence 2023
Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?
Joy van der Pol¹, Sytske Anne Bergstra², Thomas Huizinga² and CF Allaart², ¹Leiden University Medical Center, Utrecht, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD…
Abstract Number: 2431 • ACR Convergence 2023
Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages
Cong Liu¹, David Boyle¹, Adam Savage², Marie Feser³, Kristen Demoruelle³, kristine Kuhn⁴, Michael Holer³, kevin Deane³, Palak Genge², Morgan Weiss², Veronica Hernandez², Julian Reading², Jane Buckner⁵, Tom Bumol², Mark Gillespie², Peter Skene², Wei Wang⁶ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Allen Institute for Immunology, Seattle, WA, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶University of California San Diego, La Jolla, CA
Background/Purpose: Identifying molecular signatures associated with anti-citrullinated protein antibody (ACPA) positive individuals who are 'at-risk' for future RA (At-Risk) and early RA (ERA) requires comprehensive…
Abstract Number: 2483 • ACR Convergence 2023
CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort
Francesco Natalucci¹, clement triaille², Emilie Sapart², Cécile VAN MULLEM², Tatiana Sokolova³, Laurent MERIC de BELLEFON², Adrien NZEUSSEU TOUKAP², Christine GALANT⁴, Bernard Lauwerys⁵ and Patrick Durez², ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain), Anatomie pathologique, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Despite early diagnosis and the treatment-to-target strategy in ERA, the treatment response…
Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Benoît Thomas P. GILBERT¹, Raul Yhossef TITO TADEO², Céline LAMACCHIA¹, Olivia STUDER¹, Delphine COURVOISIER¹, Jeroen RAES³ and Axel Finckh⁴, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, ³Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, ⁴HUG, Geneva, Switzerland
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
Abstract Number: 0002 • ACR Convergence 2023
Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases
Xiaodong Wang, Rachel Kirk, Simon Lowry and Hua Mu, Zenas BioPharma, Waltham, MA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefits across…
Abstract Number: 0072 • ACR Convergence 2023
Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
Marie Naingeon¹, Samuel Bitoun², Matthieu roulleaux Dugage¹, Caroline de Oliveira¹, Caroline Berthot¹, Xavier Mariette³, Nathalie Chaput¹ and Gaetane Nocturne⁴, ¹LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, ²CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ³Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁴APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…
Abstract Number: 0173 • ACR Convergence 2023
Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis
Peter C. Taylor¹ and Jenya Antonova², ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA
Background/Purpose: For rheumatoid arthritis (RA) American College of Rheumatology (ACR) recommends the treating to target approach, starting with conventional synthetic antirheumatic drugs (DMARDs). ACR advises…
Abstract Number: 0344 • ACR Convergence 2023
Patient Engagement and Adherence to Digital Study Tasks: WEARable Activity Tracker Study Exploring Rheumatoid Arthritis Patients’ Disease Activity Using Patient-Reported Outcome Measures, Clinical Measures, and Biometric Sensor Data (the WEAR Study)
W. Benjamin Nowell¹, Cassie Clinton², Fenglong Xie², Yuji Su³, Laura Stradford¹, David Curtis⁴, Patrick Zueger⁵, Pankaj Patel⁶, Kelly Gavigan⁷, Shilpa Venkatachalam⁸, Esteban Rivera⁹ and Jeffrey R. Curtis³, ¹Global Healthy Living Foundation, Nyack, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Global Healthy Living Foundation, San Francisco, CA, ⁵AbbVie, Inc., Mettawa, IL, ⁶AbbVie, Inc., North Chicago, IL, ⁷Global Healthy Living Foundation, Upper Nyack, NY, ⁸Global Healthy Living Foundation, New York, NY, ⁹Global Healthy Living Foundation, Long Island City, NY
Background/Purpose: We evaluated participants' adherence to protocol-assigned capture of patient-reported outcomes (PROs) and activity tracker data in the context of an ongoing longitudinal study collecting…
Abstract Number: 0395 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA)
Patti Katz¹, Mary Nakamura², Sarah Patterson³ and Katie Stone⁴, ¹University of California San Francisco, San Rafael, CA, ²UCSF/SFVAHCS, San Francisco, CA, ³University of California San Francisco, Pacifica, CA, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Self-reported poor sleep is common in RA, but only a few small studies objectively measuring sleep have been conducted in RA. In general population…
Abstract Number: 0412 • ACR Convergence 2023
COVID Antibody Response to Third Dose Anti-SARS-COV2 mRNA Vaccine in Patients with Seropositive Rheumatoid Arthritis on Immunosuppressive Therapy
Karthik Kovuru¹, Sylwia Waz¹ and Aarti Malik², ¹University of Chicago (Northshore) Internal Medicine Residency, Chicago, IL, ²Department of Rheumatology, University of Chicago/Northshore University, Chicago, IL
Background/Purpose: Patients with immune-mediated inflammatory diseases on immunosuppressive medications are presumed to be at increased risk for hospital admissions and deaths related to COVID-19 infections.…
Abstract Number: 0429 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Andrew Garrison⁶, Yanna Song⁶, Sara K. Penn⁶, Ralph Lippe⁷, Diane Caballero⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Inc., Chicago, IL, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].